Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a variety of methods, including tried- ...

Quest Diagnostics (DGX) is gaining from strong existing customer relationships, new customer wins, broad health plan access and advanced diagnostics offerings. The stock carries a Zacks Rank #2 (Buy) currently. Quest Diagnostics has been experiencing robust volume growth in its core business (excluding COVID Testing), banking on the growth of new physician and hospital customers, a more favorable test mix with increased use of advanced diagnostics, continued strength in healthcare utilization and the ongoin ...

Quest Diagnostics Inc.'s (DGX) sustained growth momentum within the legacy base business is poised to help it grow in the upcoming quarters. Strong progress in the company's highly specialized Advanced Diagnostics offerings is encouraging. Additionally, the cost discipline program, Invigorate, is boosting productivity through automation and AI. However, a debt-laden balance sheet and challenges from fierce competition are concerning for DGX's operations. In the past year, this Zacks Rank #2 (Buy) stock has ...

Quest achieves top score of 100 on 2024 Disability Equality Index® Best Places to Work for Disability Inclusion SECAUCUS, N.J., Aug. 1, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced it has been named to the 2024 Disability Equality Index® Best Places to Work for Disability Inclusion by Disability: IN and the American Association of People with Disabilities (AAPD). Quest Diagnostics Named a 'Best Place to Work for Disability Inclusion' fo ...

Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels. DGX has seen stronger estimate revision activity and sports more attractive valuation metrics than PNTG, so it seems like value investors will conclude that DGX is the superior option right now. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The ...

Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large. One company value investors might notice is Quest Diagnostics (DGX) . DGX is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. The stock is trading with a P/E ratio of 15.65, which compares to its indust ...

BALTIMORE, Md. and MONTREAL, July 29, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, announced today a research collaboration with Dr. Simon Turcotte, hepatopancreatobiliary surgeon and scientist at Université de Montréal's affiliated hospital research centre, the CRCHUM, to utilize Haystack Oncology's personalized MRD technology (Haystack MRD™) to evaluate treatment effectiveness in patients with metastatic colorectal cancer (mCRC) with metastases confined to the liver. "O ...

文章核心观点 - 公司在Q2 2023财报中实现了营收和每股收益的小幅超预期 [3] - 公司的核心业务表现良好,包括医生、医院参考和医院PLS等分部,实现了3.2%的体量增长和5.1%的收入增长 [13] - 公司通过一系列收购扩大了在加拿大、明尼苏达州、威斯康星州和俄亥俄州的业务覆盖范围,并增强了癌症诊断服务能力 [13] - 公司提高了2024年全年收入和每股收益的指引 [13] 公司表现总结 1) 收入增长 - 公司Q2收入同比增长2.5%至24亿美元,超出市场预期1000万美元 [13] - 公司核心业务收入增长5.1%,得益于检测量增加和检测组合改善 [13] 2) 盈利能力 - 公司Q2每股收益为2.03美元,超出市场预期2美分 [13] - 公司Q2调整后营业利润率为16.6% [13] 3) 业务拓展 - 公司完成了对LifeLabs、Allina Health和OhioHealth等公司的收购,扩大了在加拿大、明尼苏达州、威斯康星州和俄亥俄州的业务覆盖范围 [13] - 公司收购PathAI Diagnostics,增强了癌症诊断服务的数字病理和人工智能能力 [13] 4) 指引提升 - 公司上调了2024年全年收入指引至95亿-95.8亿美元,每股收益指引为7.57美元-7.77美元 [13]

财务表现 - Quest Diagnostics的DIS业务在2024年第二季度实现了2,333百万美元的净收入，同比增长2.8%[148] - DS业务在同期实现了64百万美元的净收入，同比下降8.8%[148] - Quest Diagnostics的总净收入为2,397百万美元，同比增长2.5%[148] - Quest Diagnostics的运营成本和费用在2024年第二季度为2,042百万美元，同比增长2.6%[157] - Quest Diagnostics的净收入为229百万美元，同比下降2.4%[159] - Quest Diagnostics的每股 diluted earnings 为2.03美元，同比下降1.0%[159] - DIS业务占总净收入的比例为97.3%[161] - DS业务占总净收入的比例为2.7%[161] - Cost of services占总净收入的比例为66.5%[162] - Selling, general and administrative占总净收入的比例为17.4%[162] 业务增长 - 2024年6月30日三个月的业绩受到特定项目的影响，每股稀释收益减少0.32美元[164] - 2024年6月30日三个月的净收入较去年同期增长2.5%[169] - 2024年6月30日三个月的DIS收入较去年同期增长2.8%[169] - 2024年6月30日三个月的DIS基础业务收入（不包括COVID-19测试）较去年同期增长4.2%[170] - 2024年6月30日三个月的DIS体积较去年同期增长1.1%[170] - 2024年6月30日三个月的DIS每个申请的收入较去年同期增长1.6%[170] - 2024年6月30日三个月的DS收入较去年同期减少8.8%[171] 现金流和资本支出 - 公司现金及现金等价物于2024年6月30日为2.71亿美元，较2023年12月31日的6.86亿美元有所下降[204] - 2024年6月30日，公司的经营活动提供的净现金为5.14亿美元，较去年同期的5.38亿美元下降了2.4亿美元[206] - 2024年6月30日，公司的投资活动使用的净现金为4.13亿美元，较去年同期的8.4亿美元减少了4.27亿美元[208] - 2024年6月30日，公司的融资活动提供的净现金为(5.16)亿美元，较去年同期的1.13亿美元下降了6.29亿美元[209] - 公司计划在2024年投资约4.2亿美元用于资本支出，主要用于支持和发展现有业务，主要涉及实验室设备和设施的投资[217] 资金灵活性和借款额度 - 公司已达成协议收购LifeLabs、Allina Health实验室服务业务的部分资产以及OhioHealth实验室服务业务的部分资产，预计将在2024年下半年完成[218] - 公司现有信贷设施下可用的借款额度为12亿美元，包括4.52亿美元的担保应收账款信贷设施和7.5亿美元的无担保循环信贷设施[219] - 公司相信现金、经营现金流以及信贷设施的借款额度将为未来足够的资金灵活性，以满足季节性和其他运营资本需求、资本支出、债务偿还要求、现金股利、股票回购等需求[221]

文章核心观点 - Quest Diagnostics的子公司Haystack Oncology与Lisata Therapeutics公司建立研究合作关系,利用Haystack MRD技术检测转移性胰腺癌患者的循环肿瘤DNA [1][6] - Haystack MRD Early Experience Program已经超额认购,有近20家顶尖癌症研究机构参与,为今年晚些时候全国范围内推出临床检测铺平了道路 [2] - Lisata Therapeutics是一家临床阶段的制药公司,其主要产品候选药物certepetide旨在激活一种新的吸收通路,使共同给药或连接的抗癌药物能更有效地靶向和渗透实体瘤 [3][4] 行业概况 - 根据Markets And Markets的研究报告,全球MRD检测市场在2022年价值12亿美元,预计到2027年将以14%的复合年增长率增长 [8] - 该市场的增长主要由癌症和血液恶性肿瘤发病率和患病率的上升所推动 [8] 公司合作 - Haystack Oncology此前与TriSalus Life Sciences建立合作,评估TriSalus的SD-101在临床开发中的治疗反应和分子洞见 [9] - Quest Diagnostics与Ultima Genomics合作,利用后者的下一代测序技术,用于开发涉及Haystack实体瘤MRD技术的实验室自主研发检测,以及未来的临床和生物制药MRD应用 [10] 公司表现 - 过去一年,DGX股价下跌2.8%,而同期行业上涨11% [11] - DGX目前评级为买入(Zacks Rank 2) [12] - 同行业中,Globus Medical和Hims & Hers Health也是值得关注的优质股票 [13] - Globus Medical过去一年股价上涨20%,业绩持续超预期 [14][15] - Hims & Hers Health过去一年股价大涨173%,业绩也持续优于预期 [16][17]